Neurovance, Inc.

The stars aligned for Agios Pharmaceuticals, Inc. to bring former Alexion Pharmaceuticals Inc. commercial head Brian Goff on board as CEO to oversee the launch of the company's first rare disease

In positive new top-line Phase III results in the CNS space, Otsuka Pharmaceutical Co. Ltd. said its oral serotonin-norepinephrine-dopamine triple re-uptake inhibitor centanafadine hit its primary e

A further series of executive changes at Alexion Pharmaceuticals Inc. has been cautiously welcomed as an opportunity for recently appointed new CEO Ludwig Hantson to build his own team and have a

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred between Feb. 15 and M